SV2008002639A - Inhibidores macrociclicos del virus de hepatitis c ref. tip 101 slv - Google Patents

Inhibidores macrociclicos del virus de hepatitis c ref. tip 101 slv

Info

Publication number
SV2008002639A
SV2008002639A SV2006002639A SV2006002639A SV2008002639A SV 2008002639 A SV2008002639 A SV 2008002639A SV 2006002639 A SV2006002639 A SV 2006002639A SV 2006002639 A SV2006002639 A SV 2006002639A SV 2008002639 A SV2008002639 A SV 2008002639A
Authority
SV
El Salvador
Prior art keywords
optionally
ring
nitrogen
formula
inhibitors
Prior art date
Application number
SV2006002639A
Other languages
English (en)
Inventor
Kenneth Alan Simmen
Kock Herman Augustinus De
Pierre Jean-Marie Raboisson
Sandrine Marie Helene Vendeville
Lili Hu
De Vreken Wim Van
Gowan David Craig Mc
Abdellah Tahri
Dominique Louis Nestor Ghislain Surleraux
Original Assignee
Tibotec Pharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37036843&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SV2008002639(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tibotec Pharm Ltd filed Critical Tibotec Pharm Ltd
Publication of SV2008002639A publication Critical patent/SV2008002639A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

INHIBIDORES DE VHC DE FORMULA (I): (VER FORMULA); Y LOS N-ÓXIDOS, SALES Y FORMAS ESTEREOQUÍMICAMENTE ISOMÉRICAS DE ESTOS, EN LOS CUALES R1 ES ARILO O UN SISTEMA ANULAR SATURADO, PARCIALMENTE INSATURADO O COMPLETAMENTE INSATURADO DE 6 O 6 MIEMBROS, O UN SISTEMA ANULAR HETEROCICLICO BICICLO DE 8 A 12 MIEMBROS QUE CONTIENE UN NITRÓGENO, Y EN FORMA OPCIONAL UNO A TRES OXIGENO, AZUFRE O NITRÓGENO, DONDE DICHO SISTEMA ANULAR PUEDE ESTAR SUSTITUIDO EN FORMA OPCIONAL; L ES UN ENLACE DIRECTO, -O-, -O-ALCANDIILO C1-4-; -O-CO-, -O-C(=O)-NR5A- O -O-C(=O)-NR5A-ALCANDIILO-C1-4-; R2 ES HIDROGENO, -OR6, -C(=O)OR6, -C(=O)R7, -C(=O)NR5AR5B, -C(=O)NHR5C, -NR5AR5B, -NHR5C, -NHSOPNR5AR5B, -NR5ASOPR8, O -B(OR6)2; R3 Y R4 SON HIDROGENO O ALQUILO C1-6; O R3 Y R4 TOMADOS JUNTOS PUEDEN FORMAR UN ANILLO CICLOALQUILO C3-7; N ES 3, 4, 5 O 6; P ES 1 O 2; ARILO ES FENILO, NAFTILO, INDANILO, O 1, 2, 3, 4-TETRAHIDRONAFTILO, CADA UNO DE LOS CUALES PUEDE ESTAR SUSTITUIDO EN FORMA OPCIONAL HET ES UN ANILLO HETEROCICLO SATURADO, PARCIALMENTE INSATURADO O COMPLETAMENTE INSATURADO DE 5 O 6 MIEMBROS QUE CONTIENE 1 A 4 HETEROATOMOS SELECCIONADO CADA UNO EN FORMA INDEPENDIENTE DE NITRÓGENO, Y AZUFRE, QUE ESTA CONDENSADO EN FORMA OPCIONAL CON UN ANILLO BENCÉNICO, Y DONDE EL GRUPO HET COMO UN TODO PUEDE ESTAR SUSTITUIDO EN FORMA OPCIONAL; COMPOSICIONES FARMACEUTICAS QUE CONTIENEN COMPUESTOS (I) Y PROCESOS PARA PREPARAR LOS COMPUESTOS (I). TAMBIÉN SE PROPORCIONAN COMBINACIONES DISPONIBLES DE LOS INHIBIDORES DEL VHC DE FORMULA (I) CON RITONAVIR
SV2006002639A 2005-07-29 2006-07-29 Inhibidores macrociclicos del virus de hepatitis c ref. tip 101 slv SV2008002639A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05107067 2005-07-29
EP05107413 2005-08-11

Publications (1)

Publication Number Publication Date
SV2008002639A true SV2008002639A (es) 2008-07-23

Family

ID=37036843

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2006002639A SV2008002639A (es) 2005-07-29 2006-07-29 Inhibidores macrociclicos del virus de hepatitis c ref. tip 101 slv

Country Status (28)

Country Link
US (1) US7989471B2 (es)
EP (1) EP1912995B1 (es)
JP (1) JP5426163B2 (es)
KR (1) KR101074673B1 (es)
CN (1) CN101233137B (es)
AP (1) AP2473A (es)
AR (1) AR055104A1 (es)
AT (1) ATE517902T1 (es)
AU (1) AU2006274858B2 (es)
BR (1) BRPI0614670A2 (es)
CA (1) CA2617095C (es)
DK (1) DK1912995T3 (es)
EA (1) EA014646B1 (es)
GT (1) GT200600341A (es)
HK (1) HK1116772A1 (es)
IL (1) IL188283A (es)
JO (1) JO2768B1 (es)
MX (1) MX2008001395A (es)
MY (1) MY152153A (es)
NO (1) NO20081071L (es)
NZ (1) NZ564541A (es)
PE (1) PE20070221A1 (es)
SG (1) SG163613A1 (es)
SI (1) SI1912995T1 (es)
SV (1) SV2008002639A (es)
TW (1) TWI412534B (es)
UY (1) UY29705A1 (es)
WO (1) WO2007014919A1 (es)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
DK1713823T3 (da) 2004-01-30 2010-03-08 Medivir Ab HCV NS-3 serinproteaseinhibitorer
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
US7741281B2 (en) 2005-11-03 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
RU2008152171A (ru) * 2006-07-05 2010-08-10 Интермьюн, Инк. (Us) Новые ингибиторы вирусной репликации гепатита с
WO2008008776A2 (en) 2006-07-11 2008-01-17 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
EA017448B1 (ru) 2006-07-13 2012-12-28 Ачиллион Фармасьютикалз, Инк. 4-амино-4-оксобутаноиловые пептиды как ингибиторы вирусной репликации
US8343477B2 (en) 2006-11-01 2013-01-01 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
US7772180B2 (en) 2006-11-09 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7888464B2 (en) 2006-11-16 2011-02-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2008070358A2 (en) * 2006-11-16 2008-06-12 Phenomix Corporation N-cyclopropyl-hydroxyproline-based tripeptidic hepatitis c serine protease inhibitors containing an isoindole, pyrrolopyridine, pyrrolopyrimidine or pyrrolopyrazine heterocycle in the side chain
US8003604B2 (en) 2006-11-16 2011-08-23 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7763584B2 (en) 2006-11-16 2010-07-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20100323953A1 (en) * 2007-01-08 2010-12-23 Phenomix Corporation Macrocyclic hepatitis c protease inhibitors
CN105254637A (zh) * 2007-02-08 2016-01-20 爱尔兰詹森科学公司 嘧啶取代的大环抑制剂
WO2008096002A1 (en) * 2007-02-08 2008-08-14 Tibotec Pharmaceuticals Ltd. Hcv inhibiting macrocyclic phosphonates and amidophosphates
US8383583B2 (en) 2007-10-26 2013-02-26 Enanta Pharmaceuticals, Inc. Macrocyclic, pyridazinone-containing hepatitis C serine protease inhibitors
MX2010005261A (es) 2007-11-14 2010-10-15 Enanta Pharm Inc Inhibidores macrocíclicos de proteasa de serina de hepatitis c de tetrazolilo.
WO2009079353A1 (en) 2007-12-14 2009-06-25 Enanta Pharmaceuticals, Inc. Triazole-containing macrocyclic hcv serine protease inhibitors
US8202996B2 (en) 2007-12-21 2012-06-19 Bristol-Myers Squibb Company Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
MX2010010276A (es) 2008-03-20 2011-03-25 Enanta Pharm Inc Compuestos macrociclicos fluorinados como inhibidores del virus de hepatitis c.
US8163921B2 (en) 2008-04-16 2012-04-24 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7964560B2 (en) 2008-05-29 2011-06-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2300491B1 (en) 2008-05-29 2016-01-06 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US8207341B2 (en) 2008-09-04 2012-06-26 Bristol-Myers Squibb Company Process or synthesizing substituted isoquinolines
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
US8044087B2 (en) 2008-09-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8563505B2 (en) 2008-09-29 2013-10-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
NZ592668A (en) 2008-12-10 2013-12-20 Achillion Pharmaceuticals Inc New 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
US8283310B2 (en) 2008-12-15 2012-10-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
TW201040181A (en) 2009-04-08 2010-11-16 Idenix Pharmaceuticals Inc Macrocyclic serine protease inhibitors
US8232246B2 (en) 2009-06-30 2012-07-31 Abbott Laboratories Anti-viral compounds
CN101987825B (zh) * 2009-07-31 2014-04-02 上海开拓者医药发展有限公司 一种2-氨基-3-甲基-4-甲氧基苯乙酮的制备方法
US9284307B2 (en) 2009-08-05 2016-03-15 Idenix Pharmaceuticals Llc Macrocyclic serine protease inhibitors
KR20140003521A (ko) 2010-12-30 2014-01-09 이난타 파마슈티칼스, 인코포레이티드 페난트리딘 매크로사이클릭 ｃ형 간염 세린 프로테아제 억제제
CN103534256B (zh) 2010-12-30 2016-08-10 益安药业 大环丙型肝炎丝氨酸蛋白酶抑制剂
TW201309690A (zh) 2011-02-10 2013-03-01 Idenix Pharmaceuticals Inc 巨環絲胺酸蛋白酶抑制劑，其醫藥組合物及其於治療ｈｃｖ感染之用途
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
ES2563479T3 (es) * 2012-01-11 2016-03-15 Abbvie Inc. Procedimientos para elaborar inhibidores de proteasa de VHC
EP2903988A1 (en) 2012-10-08 2015-08-12 AbbVie Inc. Compounds useful for making hcv protease inhibitors
JP6154474B2 (ja) 2012-10-19 2017-06-28 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃ型肝炎ウイルス阻害剤
US9598433B2 (en) 2012-11-02 2017-03-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9334279B2 (en) 2012-11-02 2016-05-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2914614B1 (en) 2012-11-05 2017-08-16 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
EP2964664B1 (en) 2013-03-07 2017-01-11 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
CA2905433A1 (en) 2013-03-14 2014-09-25 Achillion Pharmaceuticals, Inc. Novel processes for producing sovaprevir
WO2014145507A1 (en) 2013-03-15 2014-09-18 Achillion Pharmaceuticals, Inc. A process for making a 4-amino-4-oxobutanoyl peptide cyclic analogue, an inhibitor of viral replication, and intermediates thereof
SG11201507467VA (en) 2013-03-15 2015-10-29 Achillion Pharmaceuticals Inc Sovaprevir polymorphs and methods of manufacture thereof
WO2014145600A1 (en) 2013-03-15 2014-09-18 Achillion Pharmaceuticals, Inc. Ach-0142684 sodium salt polymorphs, composition including the same, and method of manufacture thereof
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
MA41812A (fr) * 2015-03-27 2018-01-30 Janssen Pharmaceuticals Inc Procédés et intermédiaires pour la préparation d'un inhibiteur de protéase macrocyclique du vhc

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT727419E (pt) 1992-12-29 2002-08-30 Abbott Lab Compostos intermediarios para a preparacao de inibidores da protease retroviral
IL110752A (en) 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
US5559158A (en) 1993-10-01 1996-09-24 Abbott Laboratories Pharmaceutical composition
IL111991A (en) 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
US6054472A (en) 1996-04-23 2000-04-25 Vertex Pharmaceuticals, Incorporated Inhibitors of IMPDH enzyme
US5807876A (en) 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
CZ298463B6 (cs) 1996-04-23 2007-10-10 Vertex Pharmaceuticals Incorporated Deriváty mocoviny pro použití jako inhibitory IMPDH enzymu a farmaceutické prostredky, které je obsahují
ZA979327B (en) 1996-10-18 1998-05-11 Vertex Pharma Inhibitors of serine proteases, particularly hepatitis C virus NS3 protease.
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
WO1998040381A1 (en) 1997-03-14 1998-09-17 Vertex Pharmaceuticals Incorporated Inhibitors of impdh enzyme
CA2294562C (en) 1997-08-11 2005-07-26 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor peptide analogues
GB9818731D0 (en) * 1998-08-27 1998-10-21 Univ Portsmouth Compounds
EE200100492A (et) 1999-03-19 2002-12-16 Vertex Pharmaceuticals Incorporated Ensüümi IMPDH inhibiitorid
UA74546C2 (en) 1999-04-06 2006-01-16 Boehringer Ingelheim Ca Ltd Macrocyclic peptides having activity relative to hepatitis c virus, a pharmaceutical composition and use of the pharmaceutical composition
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
EP2468744A2 (en) * 2002-04-11 2012-06-27 Vertex Pharmaceuticals Incorporated Inhibitors of serine proteases, particularly HCV NS3-NS4A protease
ES2386161T3 (es) * 2003-04-16 2012-08-10 Bristol-Myers Squibb Company Proceso para separar una mezcla de enantiómeros de éster alquílico usando una enzima
US7125845B2 (en) * 2003-07-03 2006-10-24 Enanta Pharmaceuticals, Inc. Aza-peptide macrocyclic hepatitis C serine protease inhibitors
DK1713823T3 (da) 2004-01-30 2010-03-08 Medivir Ab HCV NS-3 serinproteaseinhibitorer
CN101273027B (zh) * 2005-07-29 2015-12-02 爱尔兰詹森科学公司 丙型肝炎病毒的大环抑制剂
PE20070343A1 (es) * 2005-07-29 2007-05-12 Medivir Ab Inhibidores macrociclicos del virus de la hepatitis c

Also Published As

Publication number Publication date
US7989471B2 (en) 2011-08-02
EA014646B1 (ru) 2010-12-30
IL188283A0 (en) 2008-04-13
BRPI0614670A2 (pt) 2011-04-12
SG163613A1 (en) 2010-08-30
HK1116772A1 (en) 2009-01-02
GT200600341A (es) 2007-02-26
CN101233137A (zh) 2008-07-30
KR20080041651A (ko) 2008-05-13
ATE517902T1 (de) 2011-08-15
EP1912995A1 (en) 2008-04-23
TW200745165A (en) 2007-12-16
CA2617095C (en) 2014-05-13
EA200800484A1 (ru) 2008-06-30
JO2768B1 (en) 2014-03-15
JP5426163B2 (ja) 2014-02-26
CN101233137B (zh) 2014-05-07
AP2473A (en) 2012-09-24
TWI412534B (zh) 2013-10-21
AR055104A1 (es) 2007-08-08
US20100240698A1 (en) 2010-09-23
KR101074673B1 (ko) 2011-10-19
MY152153A (en) 2014-08-15
PE20070221A1 (es) 2007-04-16
IL188283A (en) 2016-12-29
AU2006274858B2 (en) 2012-05-24
NZ564541A (en) 2010-03-26
DK1912995T3 (da) 2011-10-24
UY29705A1 (es) 2007-05-31
MX2008001395A (es) 2008-04-16
NO20081071L (no) 2008-04-25
WO2007014919A1 (en) 2007-02-08
CA2617095A1 (en) 2007-02-08
SI1912995T1 (sl) 2011-11-30
JP2009502882A (ja) 2009-01-29
AU2006274858A1 (en) 2007-02-08
EP1912995B1 (en) 2011-07-27

Similar Documents

Publication Publication Date Title
SV2008002639A (es) Inhibidores macrociclicos del virus de hepatitis c ref. tip 101 slv
SV2008002642A (es) Inhibidores macrociclicos del virus de hepatitis c ref. pit 111 slv
CL2011002377A1 (es) Compuestos derivados de heterociclos triciclicos fusionados de anillo antraceno y bifenileno, inhibidores de proteína ns5a del virus de hepatitis c (vhc); composicion farmaceutica que los comprende; y uso del compuesto en la preparacion de un medicamento util en el tratamiento de hepatitis c.
UY29016A1 (es) Analogos de dipeptidos inhibidores de la hepatitis c
GT200600165A (es) Derivados dihidrobenzofuranos y usos de los mismos
PE20130375A1 (es) Compuestos de triazolopiridinas y triazolopirazinas inhibidores de c-met y composiciones de los mismos
PE20161573A1 (es) Ciclopropilamina como inhibidor de la lsd1
AR064416A1 (es) Derivados de purina, piridina y pirimidina condensadas con heterociclos, moduladores de pka y/o pkb, composiciones farmaceuticas que los contienen, y usos para el tratamiento de enfermedades hiperproliferativas.
PE20060664A1 (es) Amidas biciclicas como inhibidores de cinasa
PE20091734A1 (es) Compuestos de 2-imino-3-metilpirrolopirimidinona fenilo-sustituida como inhibidores de bace-1, composiciones y su uso
AR075510A1 (es) Inhibidores del virus de la hepatitis c
SV2008002641A (es) Inhibidores macrociclicos del virus de hepatitis c ref. tip 138 slv
AR054465A1 (es) Concentrado para suspender en aceites
PE20140703A1 (es) Derivados de heteroarilo como moduladores de nachr alfa 7
DE602005019241D1 (de) Heterocyclische kondensierte verbindungen und ihre verwendung als antidiuretische mittel
PE20060556A1 (es) Derivados de urea ciclicos sustituidos con heterociclo como inhibidores de quinasa
SV2009003258A (es) Nuevos derivados aminopirimidina como inhibidores de plk1
PE20170249A1 (es) Acidos carboxilicos heterociclicos como activadores de guanilato ciclasa soluble
PE20121157A1 (es) Compuestos heterociclicos como inhibidores de proteasas serinas
PE20091439A1 (es) Compuestos triciclicos como antagonistas de crf
PE20080010A1 (es) Derivados de diazepina para el tratamiento de la depresion y composiciones farmaceuticas que los comprenden
PE20170295A1 (es) Compuestos de imidazopiridazina
PE20000011A1 (es) Combinacion eficaz para el tratamiento de la impotencia
PA8634501A1 (es) Derivados de tetrahidroisoquinolilsulfonamidas, su preparacion y su utilizacion en terapeutica
PE20180478A1 (es) Compuestos triciclicos y su uso como inhibidores de la fosfodiesterasa